Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

The World Health Organization (WHO) has issued a statement expressing concerns about a proposed clinical trial in Guinea-Bissau, which aims to evaluate the hepatitis B birth dose vaccine. This vaccine is crucial for preventing the transmission of hepatitis B from mothers to newborns, a significant public health challenge. The WHO has highlighted several ethical and scientific issues with the study, slated to begin in February 2026, emphasizing the potential risks to newborns if the vaccine is withheld.

For over 30 years, the hepatitis B birth dose vaccine has been a cornerstone in global health efforts to combat liver disease. It has been incorporated into national vaccination schedules in more than 115 countries, effectively reducing mother-to-child transmission of the virus. This intervention is not only vital for individual health but is also a critical component of worldwide efforts to eliminate hepatitis B. WHO officials argue that withholding such a proven vaccine from some participants in a clinical trial poses significant ethical concerns, as it exposes infants to severe health risks, including chronic infection, liver cirrhosis, and cancer.

The proposed study in Guinea-Bissau has drawn criticism due to its design, which includes a no-treatment control group. WHO contends that such a design is inappropriate and unethical, given the existing evidence of the vaccine's efficacy. According to WHO guidelines, placebo or no-treatment trials are only justified when no effective intervention exists or when the trial addresses an unresolved question of safety or efficacy. The current trial does not meet these criteria, as the vaccine's effectiveness is well-documented.

Furthermore, WHO criticizes the trial's scientific basis, suggesting that the study does not adequately justify the need for its design. The proposed trial seems to explore hypothetical safety concerns without credible evidence indicating any safety issues with the vaccine. This raises questions about the study's utility and potential biases, as it risks undermining established public health knowledge without a clear scientific rationale.

The implications of such a trial are significant, particularly for women and newborns in Guinea-Bissau. Women, who are often the primary caregivers, could face increased anxiety and uncertainty about their children's health. The potential for increased transmission rates could also place a greater burden on healthcare systems and exacerbate the existing challenges in maternal and child health in the region.

As the situation develops, it is crucial for stakeholders to consider the ethical and scientific standards that underpin clinical research involving human participants. The WHO's statement serves as a reminder of the importance of safeguarding public health interventions that have proven their worth over decades. Moving forward, it is essential for any new research to prioritize the well-being of participants and adhere to rigorous ethical guidelines to ensure that scientific progress does not come at the expense of vulnerable populations.